common glp 1 medications GLP-1 Infographic Top GLP-1 Medicines Available Today

Polycystic Ovary Syndrome (PCOS) - 5-10% of women 50% lower glutathione levels compared to women without PCOS 3-4x higher risk of preeclampsia 3x higher risk of gestational diabetes Critical concern: With 50% lower baseline glutathione, the "safe" dose is effectively cut in half IVF Conception - 2-5% of births (up to 6-8% in some countries) Women who conceive via IVF experience dramatic antioxidant depletion: 70% reduction in plasma antioxidant capacity 83% reduction in follicular fluid antioxidant capacity 50-100%+ increase in oxidative stress markers With over 5 million babies born via IVF globally, this represents a large high-risk population Gallbladder Dysfunction - 10% of pregnant women Up to 10% develop gallstones or biliary sludge Intrahepatic cholestasis: 0.4-10% of pregnancies CRITICAL: Fatal Outcomes Documented at Therapeutic Doses The first case of a pregnant woman with intrahepatic cholestasis who died from liver failure after taking THERAPEUTIC/NORMAL doses of acetaminophen was reported in 2022

GHK-Cu binds copper ions and is studied in laboratory research as a signaling molecule that may be involved in cell communication, matrix formation and regenerative processes

Tesamorelin uses pituitary feedback architecture to self-limit its effect

Alcohol disrupts this system at three distinct points

Allina Health in Minnesota cut GLP-1 coverage from its own employee health plan

This collaborative effort not only enhances the scientific robustness of the guidelines but also promotes a unified understanding and responsible management of traditional medicine practices within the international sporting community